-
Document de presse | 2021.05.12
An Asthma Vaccine Effective in Mice
Inserm teams led by Laurent Reber (Infinity, Toulouse) and Pierre Bruhns (Humoral Immunity, Institut Pasteur, Paris) and French company NEOVACS have developed a vaccine that could induce long-term protection against allergic asthma, reducing the severity of its symptoms and thus significantly improving patient quality of life. Their research in animals has been published in the journal Nature...
-
Document de presse | 2005.11.07
Malaria: an innovative approach for developing a vaccine
Researchers at the Institut Pasteur have developed a novel approach in order to design a vaccine candidate against malaria based on clinical observations in humans. Among populations infected by malaria, they sought to discover which antigens trigger immune responses capable of eliminating the Plasmodium falciparum parasite. In a phase I clinical trial, they showed that protective antibodies...
-
Article | 2017.03.21
At international the level
From its very early days, the Institut Pasteur has enjoyed support from across the world. The original international appeal, launched to provide Louis Pasteur with the resources he needed to improve vaccination against rabies, work with other scientists on a number of infectious diseases and train up new generations of scientists, met with huge success.
-
Article | 2019.06.25
Host-pathogen interactions (33 entities)
Pathogens have evolved sophisticated strategies to infect, propagate and persist within their hosts. Here, host-pathogen interactions are studied at the molecular, cellular, organ and whole-organism levels. The long-term goal of these studies is to identify novel targets for diagnosis, vaccination and treatment.
-
News | 2015.12.20
The mechanism of an AIDS vaccine candidate filmed in vivo
Using innovative technology, scientists from the Institut Pasteur and Inserm have filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response. This previously unseen footage clearly shows how the vaccine recruits the immune cells needed to destroy infected cells. These results shed new light on the...
-
Article | 2020.06.16
Spike glycoprotein, lentiviral vectors and B/T-cell vaccine
Aims: to develop as quickly as possible:an in vitro test to detect and quantify SARS-CoV-2 neutralizing antibodies while avoiding the need to handle the virus. The test will be used to demonstrate the feasibility of vaccine candidates (proof of concept).The availability of a test of this type is crucial in searching for antibodies in samples from patients with Covid-19. These...
-
News | 2022.03.22
Shigella: GMP process for a vaccine candidate from the Institut Pasteur
Intravacc announces the publication of a GMP (Good Manufacturing Practices) process for a semi-synthetic Shigella glycoconjugate vaccine candidate developed at the Institut Pasteur (Paris).Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, announced the publication of a GMP (Good Manufacturing Practices) manufacturing and formulation...
-
News | 2021.04.26
Yellow fever: understanding the rare side effects of vaccines
Preventive vaccination is a powerful tool in controlling viral outbreaks. It is important that any side effects associated with the use of vaccines are as mild as possible. Scientists from the Institut Pasteur set out to understand the reasons behind the rare neurological side effects that occasionally occur with use of the yellow fever vaccine. They studied a vaccine strain known as FNV, which...
-
News | 2015.03.01
Themis Bioscience’s Chikungunya Vaccine Study Results Published
Phase 1 trial of the vaccine candidate which was developed under an R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) shows good immunogenicity, safety and tolerability.
-
News | 2019.04.09
Meningitis: analysis of the long-term protection of the MenAfriVac vaccine
Frequent and major outbreaks of meningococcal meningitis have swept through countries in the "African meningitis belt", a region south of the Sahara that stretches from Senegal to Ethiopia, for over a century. To tackle this public health emergency, a group A polysaccharide tetanus toxoid conjugate vaccine (also called MenAfriVac) was developed against meningococcus. Using data from several...